Skip to main content
. 2021 Dec 2;8:791716. doi: 10.3389/fmed.2021.791716

Figure 5.

Figure 5

Frequencies of patients with mild/moderate and severe/critical illness within different suPAR level intervals. Patients were stratified into three suPAR level groups according to manufacturer's recommendations. A χ2 test revealed asymmetric distribution of patients with different disease severity. suPAR, soluble urokinase plasminogen activator receptor.